SG10202004535PA - Enhanced adoptive cell therapy - Google Patents
Enhanced adoptive cell therapyInfo
- Publication number
- SG10202004535PA SG10202004535PA SG10202004535PA SG10202004535PA SG10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA
- Authority
- SG
- Singapore
- Prior art keywords
- cell therapy
- adoptive cell
- enhanced
- enhanced adoptive
- therapy
- Prior art date
Links
- 238000011467 adoptive cell therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20135387 | 2013-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202004535PA true SG10202004535PA (en) | 2020-06-29 |
Family
ID=50513266
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508585PA SG11201508585PA (en) | 2013-04-18 | 2014-04-16 | Enhanced adoptive cell therapy |
SG10202004535PA SG10202004535PA (en) | 2013-04-18 | 2014-04-16 | Enhanced adoptive cell therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201508585PA SG11201508585PA (en) | 2013-04-18 | 2014-04-16 | Enhanced adoptive cell therapy |
Country Status (14)
Country | Link |
---|---|
US (2) | US10647963B2 (en) |
EP (2) | EP2986311B1 (en) |
JP (2) | JP6580555B2 (en) |
KR (3) | KR102502974B1 (en) |
CN (2) | CN105307671B (en) |
AU (2) | AU2014255733B2 (en) |
BR (1) | BR112015026417B1 (en) |
CA (1) | CA2909432A1 (en) |
DK (1) | DK2986311T3 (en) |
ES (1) | ES2708749T3 (en) |
RU (1) | RU2703438C2 (en) |
SG (2) | SG11201508585PA (en) |
WO (1) | WO2014170389A1 (en) |
ZA (1) | ZA201507790B (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2845212T3 (en) | 2009-04-13 | 2021-07-26 | Inst Nat Sante Rech Med | HPV particles and their uses |
US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
AU2014323424B2 (en) | 2013-09-18 | 2019-12-19 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
KR102608590B1 (en) * | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic tumor viruses and methods of use |
BR112017018111A2 (en) * | 2015-03-17 | 2018-04-10 | Tilt Biotherapeutics Oy | oncolytic adenovirus coding for bispecific antibodies and related methods and uses |
US20180133270A1 (en) * | 2015-05-19 | 2018-05-17 | British Columbia Cancer Agency Branch | Recombinant oncolytic viruses and uses thereof |
US20190038727A1 (en) * | 2015-09-09 | 2019-02-07 | Tvax Biomedical I, Llc | Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy |
JP6924747B2 (en) | 2015-09-16 | 2021-08-25 | アイオー バイオテック エーピーエスIO Biotech ApS | Vaccine composition containing CC motif chemokine 22 (CCL22) or a fragment thereof |
EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
MX2019000252A (en) | 2016-06-30 | 2019-10-09 | Oncorus Inc | Pseudotyped oncolytic viral delivery of therapeutic polypeptides. |
FI20165814A (en) | 2016-10-27 | 2018-04-28 | Tilt Biotherapeutics Oy | INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY |
EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
WO2018118967A1 (en) * | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
CN108261426B (en) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | Pharmaceutical composition and its application in the drug for the treatment of tumour and/or cancer |
US20190352616A1 (en) * | 2017-01-30 | 2019-11-21 | Epicentrx, Inc. | Multiple transgene recombinant adenovirus |
EA201990822A1 (en) * | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | IMMUNOMODULATING FUSION PROTEINS |
EP3610026A4 (en) * | 2017-04-14 | 2021-03-24 | Cold Genesys, Inc. | Methods of treating bladder cancer |
CA3063695A1 (en) * | 2017-05-17 | 2018-11-22 | Seattle Children's Hospital (Dba Seattle Children's Research Institute | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
CN109276580B (en) | 2017-07-21 | 2021-08-24 | 厦门大学 | A virus for treating tumor |
JP2020529847A (en) * | 2017-08-03 | 2020-10-15 | タイガ バイオテクノロジーズ,インク. | Methods and compositions for the treatment of cancer |
CN111148533A (en) | 2017-09-19 | 2020-05-12 | 麻省理工学院 | Compositions for chimeric antigen receptor T cell therapy and uses thereof |
CN109554353B (en) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | Isolated recombinant oncolytic poxvirus, pharmaceutical compositions and use thereof in a medicament for the treatment of tumors and/or cancers |
CN109576231B (en) | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions and their use in medicaments for the treatment of tumors and/or cancers |
CN107759701B (en) * | 2017-10-27 | 2021-07-02 | 杭州优善生物科技有限公司 | Chimeric antigen receptor, NK cell modified by chimeric antigen receptor, coding DNA, mRNA, expression vector, preparation method and application |
US12036257B2 (en) | 2017-10-31 | 2024-07-16 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
US11896635B2 (en) | 2017-11-08 | 2024-02-13 | Kagoshima University | Oncolytic virus (oncolytic immunotherapy) capable of effectively treating even metastatic cancer while ensuring safety, with expression control system providing optimal expression level of mounted immunogenic gene |
WO2019125981A1 (en) | 2017-12-19 | 2019-06-27 | Musc Foundation Of Research Development | T regulatory (trey) cell translantation in osteogenesis imperfecta (oi) |
WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
CN108017716B (en) * | 2018-01-02 | 2021-03-19 | 赖沛龙 | Chimeric antigen receptor comprising C5aR intracellular domain, lentiviral vector, expression cell and drug |
GB201801067D0 (en) * | 2018-01-23 | 2018-03-07 | Price Nicola Kaye | Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
CN110101843A (en) * | 2018-02-01 | 2019-08-09 | 北京科诺科服生物科技有限公司 | A kind of anti-tumor protein and its application |
GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
KR20210030973A (en) | 2018-07-11 | 2021-03-18 | 액팀 테라퓨틱스, 인코퍼레이티드 | Engineered immunostimulatory bacterial strains and uses thereof |
JP2022502037A (en) | 2018-09-28 | 2022-01-11 | マサチューセッツ インスティテュート オブ テクノロジー | Immunomodulatory molecules localized to collagen and their methods |
JP2022521268A (en) * | 2019-02-21 | 2022-04-06 | アンリーシュ イミュノ オンカリティクス,インコーポレイテッド | Oncolytic adenovirus vector and usage |
US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
KR20220004959A (en) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
EP3983004A1 (en) * | 2019-06-14 | 2022-04-20 | TILT Biotherapeutics Oy | Oncolytic adenovirus and checkpoint inhibitor combination therapy |
EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
KR20220092523A (en) | 2019-10-11 | 2022-07-01 | 틸트 바이오세러퓨틱스 오이 | Oncolytic viral vector encoding variant interleukin-2 (vIL-2) polypeptide |
KR20220113943A (en) | 2019-11-12 | 2022-08-17 | 액팀 테라퓨틱스, 인코퍼레이티드 | Immunostimulatory bacterial delivery platforms and uses thereof for delivery of therapeutic products |
CN115485295A (en) | 2020-03-10 | 2022-12-16 | 麻省理工学院 | Compositions and methods for immunotherapy of NPM1 c-positive cancers |
JP2023517063A (en) | 2020-03-10 | 2023-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | Methods and compositions for generating engineered memory-like NK cells |
JP2023521076A (en) * | 2020-04-07 | 2023-05-23 | シェンチェン ホァ ヤオ カン ミン バイオファーマシューティカル カンパニー リミテッド | Engineered oncolytic adenovirus |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
EP4196139A2 (en) | 2020-08-12 | 2023-06-21 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
RU2753742C1 (en) * | 2020-10-16 | 2021-08-24 | Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | RECOMBINANT STRAIN OF Ad6-hTERT-GMCSF CONTAINING EMBEDDING OF THE HUMAN TELOMERASE PROMOTER hTERT, AS WELL AS HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, WHICH HAS SELECTIVE CYTOLYTIC ACTIVITY AGAINST TELOMERASE-POSITIVE TUMOR CELLS AND EXPRESSES ACTIVE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR |
CN112481284B (en) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | mRNA (messenger ribonucleic acid) encoding CAR (CAR-T) gene, combined mRNA, construction method, CAR-T cell and application |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
BR112023022681A2 (en) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | ONCOLYTIC VIRUSES FOR MODIFIED MHC EXPRESSION |
EP4349975A1 (en) * | 2021-05-25 | 2024-04-10 | Voncolytic Therapeutics Co., Ltd. | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment |
CN113249342B (en) * | 2021-05-25 | 2023-12-01 | 江苏万戎生物医药科技有限公司 | Chimeric broad-spectrum oncolytic adenovirus with multiple mechanism synergistic and synergistic immunotherapy and application thereof in tumor treatment |
CN113398249A (en) * | 2021-07-08 | 2021-09-17 | 中国人民解放军空军军医大学 | Application of over-expressed chemokine CCL14 in preparation of medicine for treating tumors under participation of immune system |
CN113832115A (en) * | 2021-08-25 | 2021-12-24 | 居颂光 | Fusion gene RIL-7 combined CCL19 recombinant oncolytic vaccinia virus and application thereof in preparation of antitumor drugs |
KR20240073042A (en) * | 2021-10-04 | 2024-05-24 | 틸트 바이오세러퓨틱스 오이 | Oncolytic viral vector encoding interleukin-7 (IL-7) polypeptide |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
CN118234851A (en) * | 2021-11-19 | 2024-06-21 | 南开大学 | Recombinant armed oncolytic viral compositions and their use in TIL adoptive therapy |
WO2023194656A1 (en) | 2022-04-08 | 2023-10-12 | Tilt Biotherapeutics Oy | Monoclonal pd-l1 antibodies |
TW202408554A (en) * | 2022-05-09 | 2024-03-01 | 大陸商杭州微諾邁博生物科技有限公司 | Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy |
CN115969971B (en) * | 2022-11-24 | 2023-08-18 | 珠海恩科生物科技有限公司 | Application of composition in preparation of medicines for treating tumors |
KR102603628B1 (en) * | 2023-06-29 | 2023-11-16 | 국방과학연구소 | Composition for differentiating, proliferating or activating natural killer cells, method for differentiating, proliferating or activating natural killer cells using the same, and natural killer cells cultured thereby |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1290249C (en) * | 1986-04-09 | 1991-10-08 | Cetus Corporation | COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR |
US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
FR2709309B1 (en) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Cellular compositions, preparation and therapeutic uses. |
GB9927328D0 (en) | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
EP1191105A1 (en) | 2000-09-25 | 2002-03-27 | Galapagos Genomics B.V. | Gene delivery vectors provided with a tissue tropism for T-lymphocytes |
ITMI20012110A1 (en) | 2001-10-12 | 2003-04-12 | Keryos Spa | MULTI-CISTRONIC VECTORS USABLE IN GENE TRANSFER PROTOCOLS |
US20060062764A1 (en) | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
ES2276623B1 (en) * | 2005-12-12 | 2008-06-01 | Proyecto De Biomedicina Cima, S.L | NEW ADENOVIRUS RECOMBINANTS OF CONDITIONED REPLICATION (CRAD). |
WO2007093036A1 (en) | 2006-02-13 | 2007-08-23 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
EP2356219A4 (en) | 2008-10-08 | 2017-07-05 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
ES2612889T3 (en) | 2008-12-22 | 2017-05-19 | Targovax Oy | Oncolytic adenoviral vectors and related procedures and uses |
FI20090030A0 (en) | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Oncolytic virus |
US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US9487800B2 (en) | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
AU2011306846B2 (en) | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
CN102154213B (en) * | 2011-01-19 | 2012-07-25 | 郑骏年 | Novel cytokine-induced killer (CIK) cells for carrying cytokine loaded double-regulated oncolytic adenovirus |
CN103476943A (en) * | 2011-03-10 | 2013-12-25 | 普罗维克图斯药品公司 | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
-
2014
- 2014-04-16 EP EP14718086.3A patent/EP2986311B1/en active Active
- 2014-04-16 RU RU2015148920A patent/RU2703438C2/en active
- 2014-04-16 US US14/254,235 patent/US10647963B2/en active Active
- 2014-04-16 KR KR1020227013281A patent/KR102502974B1/en active IP Right Grant
- 2014-04-16 WO PCT/EP2014/057776 patent/WO2014170389A1/en active Application Filing
- 2014-04-16 AU AU2014255733A patent/AU2014255733B2/en active Active
- 2014-04-16 CN CN201480034158.9A patent/CN105307671B/en active Active
- 2014-04-16 EP EP18204379.4A patent/EP3461491A1/en active Pending
- 2014-04-16 CN CN202010731917.4A patent/CN111658670A/en active Pending
- 2014-04-16 KR KR1020217019841A patent/KR20210084651A/en not_active IP Right Cessation
- 2014-04-16 BR BR112015026417-4A patent/BR112015026417B1/en active IP Right Grant
- 2014-04-16 ES ES14718086T patent/ES2708749T3/en active Active
- 2014-04-16 JP JP2016508153A patent/JP6580555B2/en active Active
- 2014-04-16 DK DK14718086.3T patent/DK2986311T3/en active
- 2014-04-16 KR KR1020157033014A patent/KR20160002971A/en not_active IP Right Cessation
- 2014-04-16 SG SG11201508585PA patent/SG11201508585PA/en unknown
- 2014-04-16 CA CA2909432A patent/CA2909432A1/en active Pending
- 2014-04-16 SG SG10202004535PA patent/SG10202004535PA/en unknown
-
2015
- 2015-10-19 ZA ZA2015/07790A patent/ZA201507790B/en unknown
-
2016
- 2016-11-15 US US15/351,476 patent/US10787645B2/en active Active
-
2019
- 2019-08-14 AU AU2019216631A patent/AU2019216631B2/en active Active
- 2019-08-28 JP JP2019155755A patent/JP7114532B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201507790B (en) | Enhanced adoptive cell therapy | |
IL263026A (en) | Ibrutinib combination therapy | |
HK1223553A1 (en) | Cell | |
AU356417S (en) | Battery | |
GB201303814D0 (en) | Battery structure | |
EP2988346A4 (en) | Cell case | |
GB201308440D0 (en) | Therapeutic | |
GB201310755D0 (en) | Therapy | |
GB201310031D0 (en) | Cell | |
GB201312332D0 (en) | Cell locations | |
EP2953200A4 (en) | Battery | |
GB201207305D0 (en) | Therapy | |
HK1202710A1 (en) | Laminate cell | |
GB201318668D0 (en) | Sonosensitive therapeutic | |
IL238174A0 (en) | Combination therapy with volasertib | |
GB201307269D0 (en) | Combination Therapy | |
GB201304038D0 (en) | Treated cells and therapeutic uses | |
GB201518731D0 (en) | Tumour Therapy | |
GB201304514D0 (en) | Cell delivery | |
HK1221640A1 (en) | Therapeutic peptide-expressing cells | |
GB201317589D0 (en) | Cell | |
EP2996684A4 (en) | Therapeutic methods | |
GB201320573D0 (en) | T Cell | |
TWM476369U (en) | Battery structure improvement | |
GB201309967D0 (en) | Therapeutic combinations |